New study from Spain below.
Three of my favorite PCa subjects (they also looked at testorsterone [T] as well as MetS & CRP, but there is no mention of their T findings in the Abstract, so T was presumably not positively associated.)
"A total of 524 patients were analysed, being 195 (37.2%) subsequently diagnosed with PCa and 240 (45.8%) met the diagnostic criteria for MetS. Among patients with PCa, MetS-diagnosis was present in 94 (48.2%). Remarkably, a higher risk of significant-PCa was associated to MetS, greater number of MetS-components and higher CRP levels (odds-ratio: 1.83 ...)"
"Moreover, higher circulating CRP levels were also associated with a more aggressive Gleason score in PCa patients."
"Altogether, our data reveal a clear association between the presence of MetS, a greater number of MetS-components or CRP levels >2.5 mg/L with an increased significant-PCa diagnosis and/or with aggressive features, suggesting that MetS and/or CRP levels might influence PCa pathophysiology."
At any stage, inflammation makes a bad situation worse, but can be controlled. Nalakrats got his CRP down to zero at one point - possibly the only man here to do that.
The MetS is a challenge for many - particularly when on ADT. Metformin, of course, addresses certain aspects of the MetS.
-Patrick
ncbi.nlm.nih.gov/pubmed/304...
J Cell Mol Med. 2018 Nov 18. doi: 10.1111/jcmm.13994. [Epub ahead of print]
Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
Gómez-Gómez E1,2,3, Carrasco-Valiente J1,2, Campos-Hernández JP1,2, Blanca-Pedregosa AM1, Jiménez-Vacas JM1,3,4, Ruiz-García J1,2, Valero-Rosa J1,2, Luque RM1,3,4, Requena-Tapia MJ1,2.
Author information
1
Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain.
2
Department of Urology, Reina Sofia University Hospital, Cordoba, Spain.
3
Department of Cell Biology, Physiology and Immunology, University of Cordoba (UCO), Cordoba, Spain.
4
CIBER Physiopathology of Obesity and Nutrition (CIBERobn), Madrid, Spain.
Abstract
Recently, the influence that metabolic syndrome (MetS), hormonal alterations and inflammation might have on prostate cancer (PCa) risk has been a subject of controversial debate. Herein, we aimed to investigate the association between MetS-components, C-reactive protein (CRP) and testosterone levels, and the risk of clinically significant PCa (Sig-PCa) at the time of prostate biopsy. For that, men scheduled for transrectal ultrasound guided biopsy of the prostate were studied. Clinical, laboratory parameters and criteria for MetS characterization just before the biopsy were collected. A total of 524 patients were analysed, being 195 (37.2%) subsequently diagnosed with PCa and 240 (45.8%) meet the diagnostic criteria for MetS. Among patients with PCa, MetS-diagnosis was present in 94 (48.2%). Remarkably, a higher risk of Sig-PCa was associated to MetS, greater number of MetS-components and higher CRP levels (odds-ratio: 1.83, 1.30 and 2.00, respectively; P < 0.05). Moreover, higher circulating CRP levels were also associated with a more aggressive Gleason score in PCa patients. Altogether, our data reveal a clear association between the presence of MetS, a greater number of MetS-components or CRP levels >2.5 mg/L with an increased Sig-PCa diagnosis and/or with aggressive features, suggesting that MetS and/or CRP levels might influence PCa pathophysiology.
KEYWORDS:
C-reactive protein; inflammation; metabolic syndrome; significant prostate cancer; testosterone
PMID: 30450757 DOI: 10.1111/jcmm.13994
